A cyclic peptide discovery company using trillion-scale peptide libraries, screening, and chemical optimization for internal programs and partnerships. Its website identifies oral peptide therapeutics as one potential application.
The issuer announced a $7.5 million Seed+ round without naming the strategic lead or London investor. BlueRun’s role in2021 should not be transferred to the2026 round.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
A cyclic peptide discovery company using trillion-scale peptide libraries, screening, and chemical optimization for internal programs and partnerships. Its website identifies oral peptide therapeutics as one potential application.
Program / service
Target / indication
Representative stage
Evidence & scope
Cyclic peptide discovery and partnering platform
Not disclosed · Not disclosed
未披露
No human oral results confirmed
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
20n Bio announced $7.5 million in Seed+ financing to advance AI-enabled cyclic peptide discovery, screening workflows, and its therapeutic pipeline. The company identifies oral peptides among potential applications but has not disclosed a validated clinical oral cyclic peptide candidate or human oral pharmacokinetics. The strategic lead investor was unnamed; investors from earlier rounds should not be assigned to this financing.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
